About this podcast:
This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center.
Dr Rosenberg focuses on:
- The background and previous data of immune checkpoint blockade as monotherapy and in combination with chemotherapy, in urothelial cancer
- The potential role of Immunogenic Cell Death and whether it has a clinical impact on patient care and creating an anti-tumor immune response
- Enfortumab vedotin, an ADC targeting Nectin-4
For more information, go to IO360summit.com.
Speakers
Jonathan Rosenberg, MD
Chief, Genitourinary Oncology Service, Division of Solid Tumor Oncology
Memorial Sloan Kettering Cancer Center
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.